Markets:

Overview

News

Currencies

International

Treasuries

Amgen (NQ:AMGN)

403.82 -4.01 (-0.98%)

Streaming Delayed Price Updated: 11:16 AM EDT, Aug 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Amgen

< Previous 1 2

...

20 21 22 23 24 25 26 27 28

...

69 70 Next >

A Closer Look at Amgen's Options Market Dynamics ↗

October 23, 2024

Via Benzinga

Navigating 14 Analyst Ratings For Amgen ↗

October 22, 2024

Via Benzinga

Is Amgen Stock a Buy? ↗

October 18, 2024

This biotech leader could be poised to rally higher.

Via The Motley Fool

Looking Into Amgen's Recent Short Interest ↗

October 17, 2024

Via Benzinga

Why Amgen's Obesity Drug — And $5 Billion Opportunity — Led To A Downgrade ↗

October 14, 2024

The analyst is closely watching MariTide, a potential monthly injection to treat obesity.

Via Investor's Business Daily

In-Depth Examination Of 11 Analyst Recommendations For Amgen ↗

October 14, 2024

Via Benzinga

Blue Skies, New Highs Remain Disciplined And Do Not Chase Extended Ideas ↗

October 13, 2024

It is Fall clean up time. Sell lagging and sagging companies.

Via Talk Markets

(AMGN) - Analyzing Amgen's Short Interest ↗

September 30, 2024

Via Benzinga

Analyst Expectations For Amgen's Future ↗

September 25, 2024

Via Benzinga

Market Whales and Their Recent Bets on AMGN Options ↗

September 24, 2024

Via Benzinga

Novo Nordisk, Eli Lilly Could Face Downward Pressure Despite Market Dominance From Potentially 16 New Obesity Drugs: See The Names ↗

October 11, 2024

The $200B GLP-1 market is set to expand with 16 new obesity drugs launching by 2029, challenging Novo Nordisk and Eli Lilly's dominance while addressing scalability and pricing concerns.

Via Benzinga

2 Top Dividend Stocks to Buy Hand Over Fist Right Now ↗

October 11, 2024

Income stocks can be wise additions to your portfolio in any market environment.

Via The Motley Fool

18 Stocks To Buy, 7 To Sell This Earnings Season: Goldman Sachs Calls It 'The Year Of The Stock Picker' ↗

October 10, 2024

Goldman Sachs identifies 18 stocks for potential earnings upside and advises options-based strategies in a volatile market. 10% upside for S&P 500.

Via Benzinga

Topics Stocks

Deere, Amgen, Copart And More: CNBC's 'Final Trades' ↗

October 10, 2024

On CNBC's "Halftime Report Final Trades," Jim Lebenthal of Cerity Partners named Deere & Company as his final trade.

Via Benzinga

Biden Administration Unveils Plan To Provide Generic Drugs for $2 to Medicare Recipients ↗

October 09, 2024

The Biden administration's proposed Medicare $2 Drug List Model aims to provide low-cost generic drugs for seniors and people with disabilities, with copayments capped at $2 per month for essential...

Via Benzinga

2 Biotech Stocks to Buy Hand Over Fist in October ↗

October 09, 2024

These longtime leading biotech stocks still have plenty of upside ahead.

Via The Motley Fool

Want to Invest in the Weight Loss Boom? Consider Buying These 2 Stocks ↗

October 08, 2024

Investing in the most popular players in the space isn't the only valid approach.

Via The Motley Fool

3 Magnificent Dividend Stocks to Buy in October ↗

October 06, 2024

These dividend stocks are great picks as the fall season gets underway.

Via The Motley Fool

Should You Buy the Dip on This Top Growth Stock? ↗

October 05, 2024

The biotech needs to overcome an issue most drugmakers face at some point.

Via The Motley Fool

As Weight-Loss Drugs Battle, Upstart Viking Therapeutics Threatens Eli Lilly, Novo Nordisk, Pfizer ↗

October 04, 2024

Viking Therapeutics is an upstart in the weight-loss drugs space. But it's catching attention.

Via Investor's Business Daily

Eli Lilly Leads S&P Health Care Stocks With 1,241% Gain. But The Others Aren't Slackers. ↗

October 03, 2024

Eli Lilly has gained markedly over the past decade. But it's not the only S&P 500 health care stock to notch a bullish gain.

Via Investor's Business Daily

Topics Stocks

Federal Judge Rules Amgen Must Face Tax Liability Lawsuit That Alleges Reckless Concealment Of $10.7B Tax Bill ↗

October 02, 2024

Amgen faces a class-action lawsuit over allegations of concealing a $10.7 billion tax dispute with the IRS, with shareholders accusing the company of delaying critical disclosures. A federal judge...

Via Benzinga

Topics Lawsuit

AskSlim Market Week - Friday, Sep. 27 ↗

September 27, 2024

An analysis and commentary on the financial markets.

Via Talk Markets

Stock Market Rally Hits Fresh Highs, Fueled By Micron Earnings, China Stimulus: Weekly Review ↗

September 27, 2024

The S&P 500 hit record highs, fueled by Micron and Chinese stimulus.

Via Investor's Business Daily

Topics Stocks

Taiwan Semiconductor, American Tower, Trane Technologies And A Health Care Stock On CNBC's 'Final Trades' ↗

September 26, 2024

Analyst Stephen Weiss of Short Hills Capital Partners said he still finds Taiwan Semiconductor Manufacturing Company cheap.

Via Benzinga

Amgen's Rocatinlimab Has Commercial Potential Despite Competitive Landscape, Says Goldman Sachs ↗

September 25, 2024

Amgen releases Phase 3 trial data for rocatinlimab and Uplizna, with analysts projecting strong sales despite competition in the atopic dermatitis and myasthenia gravis markets. Attention shifts to...

Via Benzinga

Argenx Stock Surges As Amgen Struggles To Take On 'The King' In Autoimmune Diseases ↗

September 25, 2024

Amgen tested its drug, Uplizna, in generalized myasthenia gravis, a market where Argenx's Vyvgart leads.

Via Investor's Business Daily

Amgen's Rocatinlimab Data Beats Placebo In Atopic Dermatitis Trial, But Analyst Says Data Raises Concerns Amid Competitive Market ↗

September 25, 2024

Amgen reports mixed results from Phase 3 trials, with rocatinlimab showing moderate success in atopic dermatitis and Uplizna outperforming expectations in myasthenia gravis, offering less frequent...

Via Benzinga

Why Is Regeneron Pharmaceuticals Stock Trading Lower On Tuesday? ↗

September 24, 2024

Regeneron filed an appeal after a court's decision, which was issued under seal.

Via Benzinga

2 Weight-Loss Stocks That Could Rocket Higher This Year ↗

September 24, 2024

Upcoming clinical trial results could push these stocks through the roof before 2024 is finished.

Via The Motley Fool

< Previous 1 2

...

20 21 22 23 24 25 26 27 28

...

69 70 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.